Citigroup Inc. Has $3.04 Million Holdings in Nuvalent, Inc. $NUVL

Citigroup Inc. lessened its holdings in Nuvalent, Inc. (NASDAQ:NUVL) by 74.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,160 shares of the company’s stock after selling 104,033 shares during the period. Citigroup Inc.’s holdings in Nuvalent were worth $3,041,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Eastern Bank bought a new stake in shares of Nuvalent during the 3rd quarter valued at approximately $52,000. Persistent Asset Partners Ltd bought a new stake in shares of Nuvalent during the second quarter worth $88,000. PNC Financial Services Group Inc. grew its stake in shares of Nuvalent by 38.2% during the second quarter. PNC Financial Services Group Inc. now owns 1,632 shares of the company’s stock worth $125,000 after buying an additional 451 shares during the last quarter. Compass Wealth Management LLC acquired a new position in shares of Nuvalent during the third quarter worth $172,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Nuvalent by 23.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,142 shares of the company’s stock valued at $240,000 after acquiring an additional 588 shares during the last quarter. Institutional investors own 97.26% of the company’s stock.

Nuvalent Stock Performance

NASDAQ:NUVL opened at $100.13 on Friday. The company has a market capitalization of $7.28 billion, a PE ratio of -17.12 and a beta of 1.32. Nuvalent, Inc. has a fifty-two week low of $55.53 and a fifty-two week high of $113.01. The company has a 50 day simple moving average of $103.14 and a two-hundred day simple moving average of $95.72.

Analysts Set New Price Targets

NUVL has been the subject of several research reports. Barclays set a $152.00 target price on Nuvalent in a research report on Monday, November 17th. Canaccord Genuity Group assumed coverage on shares of Nuvalent in a report on Wednesday, November 12th. They issued a “buy” rating and a $126.00 price objective for the company. Truist Financial set a $140.00 target price on shares of Nuvalent in a research report on Monday, November 24th. JPMorgan Chase & Co. decreased their price target on shares of Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Finally, Leerink Partners lifted their price target on shares of Nuvalent from $140.00 to $149.00 and gave the stock an “outperform” rating in a report on Monday, November 17th. Fifteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $138.67.

Key Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: HC Wainwright raised quarterly EPS forecasts for Q1–Q4 2026 and mid‑2026 quarters (cuts to expected losses: Q1 to ($1.26), Q2 to ($1.21), Q3 to ($1.16), Q4 to ($0.94)), and improved FY2026 to ($4.57) from a larger loss — signaling an expectation for accelerating progress toward profitability. MarketBeat article
• Positive Sentiment: HC Wainwright increased long‑range profitability views for FY2028 and FY2030 (FY2028 to $2.11 EPS from $1.75; FY2030 at $2.59), indicating confidence in Nuvalent’s longer-term product/market potential. MarketBeat article
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $155 price target — a bullish signal that may support upside if operational/clinical catalysts meet expectations, but it’s based on multi‑year recovery assumptions. MarketBeat article
• Neutral Sentiment: Market context: the company still shows a consensus near‑term full‑year loss (current consensus FY2026 ≈ ($3.86) per share) and a relatively high beta, so revisions can produce outsized intraday moves. MarketBeat article
• Negative Sentiment: HC Wainwright lowered FY2027 and FY2029 forecasts (FY2027 to ($2.06) from ($1.69); FY2029 to $6.52 from $6.77), showing some downward revision to intermediate/out‑year expectations and adding uncertainty to the profit ramp timeline. MarketBeat article

Insider Buying and Selling

In related news, insider Deborah Ann Miller sold 14,300 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $110.16, for a total transaction of $1,575,288.00. Following the sale, the insider owned 59,634 shares in the company, valued at $6,569,281.44. This represents a 19.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alexandra Balcom sold 7,084 shares of Nuvalent stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $110.32, for a total value of $781,506.88. Following the completion of the sale, the chief financial officer owned 54,650 shares of the company’s stock, valued at approximately $6,028,988. The trade was a 11.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 76,463 shares of company stock worth $7,722,489 over the last three months. Insiders own 10.20% of the company’s stock.

Nuvalent Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.